Physician profile
Lisa D Smith
NPI 1952369043
$6,042.57
in general payments reported to CMS, 2019-2025
53 companies · $2,558 in 2025
The $2,558 reported for 2025 was more than what 95% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $731 · 2022: $782 · 2023: $1,070 · 2024: $902 · 2025: $2,558.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,151 · Long Term Medical Supply Or Device Loan: $1,180 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,151.23 |
| Long Term Medical Supply Or Device Loan | $1,180.03 |
| Education | $198.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,727.48 | 2021-2025 | |
| Celgene Corporation | $362.36 | 2022-2025 | Reblozyl, Pomalyst, Opdualag |
| Merck Sharp & Dohme LLC | $331.64 | 2021-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Astellas Pharma US INC | $255.55 | 2025 | Vyloy |
| Pfizer INC. | $214.46 | 2021-2025 | |
| Incyte Corporation | $181.27 | 2021-2025 | Jakafi, Monjuvi, Niktimvo |
| Regeneron Healthcare Solutions, INC. | $166.24 | 2022-2025 | Libtayo |
| E.R. Squibb & Sons, L.L.C. | $163.50 | 2022-2025 | Opdivo, Eliquis, Krazati |
| Eisai INC. | $158.76 | 2021-2025 | |
| Lilly USA, LLC | $152.67 | 2021-2025 | Verzenio, Jaypirca, Retevmo |
| Novocure INC. | $141.93 | 2021-2024 | Optune |
| Genentech USA, INC. | $141.17 | 2021-2025 | Phesgo, Venclexta, Perjeta |
| Seagen INC. | $118.05 | 2021-2023 | Padcev, Tukysa |
| Abbvie INC. | $110.05 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $106.64 | 2021-2025 | Calquence |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.